Nicotinamide mononucleotide (NMN) is a bioactive metabolite with promising anti-aging properties. It is found naturally in many foods, and is orally bioavailable. However, clinical trials are needed to determine its effectiveness and safety.
NMN has been shown to have therapeutic effects on age-related cardiovascular complications, cognitive decline, and neurological dysfunctions. It has also been found to reduce oxidative stress in the body.
NMN is an intermediate by-product in two pathways for the synthesis of NAD+, the NAMPT pathway and the Preiss-Handler pathway. It is believed that aging is a consequence of a loss of NAD+. Increasing NAD+ levels can reverse the aging process.
The pharmacological activities of nicotinamide have been studied extensively for its effects on Alzheimer’s disease and other age-related diseases. Studies have revealed that the molecule may help to improve neuronal function, reversing age-related behavioural dysfunctions, and reducing the accumulation of reactive oxygen species (ROS) and DNA damage.
Nicotinamide mononucleotide can be absorbed orally, and it is quickly converted into NAD+ in the tissue. Nicotinamide mononucleotide is an effective precursor of nicotinamide adenine dinucleotide (NAD+) and may slow the onset of aging.
Nicotinamide riboside, another potential NMN booster, has been found to prevent age-related hearing loss in CSBm/m mice. Moreover, a dose of nicotinamide riboside has been shown to increase the outer hair cell count in a mouse model of alopecia areata.
Nicotinamide mononucleotide also helps in restoring the quality of oocytes of aged animals. There are also studies linking NMN to cardiovascular disease, diabetes, and cognitive impairment.